Vectura Group (VEC) Receives “Buy” Rating from N+1 Singer
Several other equities research analysts have also recently issued reports on VEC. Royal Bank of Canada upgraded Vectura Group to a sector performer rating and set a GBX 119 ($1.64) price target for the company in a research note on Thursday, December 14th. Shore Capital reiterated a buy rating on shares of Vectura Group in a research note on Thursday, January 4th. Peel Hunt reiterated a hold rating and issued a GBX 160 ($2.21) price target on shares of Vectura Group in a research note on Thursday, January 4th. Numis Securities reiterated a buy rating and issued a GBX 170 ($2.35) price target on shares of Vectura Group in a research note on Thursday, January 4th. Finally, JPMorgan Chase & Co. cut their price target on Vectura Group from GBX 170 ($2.35) to GBX 140 ($1.93) and set an overweight rating for the company in a research note on Friday, January 5th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Vectura Group presently has an average rating of Buy and a consensus target price of GBX 139.38 ($1.93).
Shares of VEC stock opened at GBX 72.85 ($1.01) on Wednesday. Vectura Group has a 12 month low of GBX 70 ($0.97) and a 12 month high of GBX 166.97 ($2.31).
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.